Seqens is a France-based global contract development and manufacturing organization (CDMO) and specialty chemicals producer serving the pharmaceutical and life sciences industries. The group provides process development and GMP manufacturing of small-molecule active pharmaceutical ingredients (APIs), advanced intermediates and fine chemicals, including complex and highly potent compounds. Seqens operates R&D centers and multipurpose plants across Europe, North America and Asia to support projects from early development through commercial supply.
Beyond small molecules, Seqens develops specialty ingredients and performance materials for healthcare and industrial applications, such as lubricant additives and advanced polymers. Through CELLforCURE by Seqens, the group offers European GMP capacity for advanced therapy medicinal products (ATMPs), including cell and gene therapies. Seqens also manufactures high-performance polymers for medical devices, including PEKK for long-term implantable applications under license. Its capabilities span route design, scale-up, analytical services and quality control within global regulatory frameworks.
To provide comprehensive coverage, we aggregate data and news under the name Seqens, encompassing the following company names, divisions, and related entities:
SEQENS SAS, SEQENS, and CELLforCURE by SEQENS.
This list encompasses current and former names, alternate names, and key divisions associated with Seqens, ensuring you can easily find all relevant information under a single, unified profile.